SIMULATIONS PLUS INC (SLP)
Health Care · NASDAQ
Pharmaceutical simulation and modeling software company enabling drug developers to predict efficacy and safety earlier, faster, and more cost-effectively.
What SIMULATIONS PLUS INC does
Simulations Plus develops and licenses specialized software for modeling and simulation in pharmaceutical research and development, clinical trial design, and regulatory support. The company provides both software products and professional services to pharmaceutical, biotech, and healthcare companies. Its platform helps customers predict drug behavior, optimize dosing, and accelerate the drug development process.
Themes: []
Fundamentals
- Price$18.34 as of 2026-07-09 close
- Market cap$370M as of 2026-07-10
- 1-year return+4.6% as of 2026-07-09 close
- Net margin-78.0% as of 2026-07-10
- Gross margin+62.0% as of 2026-07-10
- ROE-49.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+2.5% as of 2026-07-10
- Revenue CAGR (3y)+13.7% SEC XBRL
- Beta1.34 as of 2026-07-10
Dividend: yield +0.6%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
[]
Competitors & peers
- Certara (drug development software and CRO services)
- Pharsight (part of Certara)
- PharMetrics (pharmacokinetic research data)
- Genedata (drug discovery informatics)
- Schrödinger (computational chemistry and drug discovery)
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations (CROs)
- Regulatory agencies
- Unprofitable operations with -77.96% net margin, though recent quarters show a return to profitability; accumulated deficit of $25.6M as of May 2026
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.